Insulin resistance and coronary flow velocity reserve in patients with autosomal dominant polycystic kidney disease

被引:8
|
作者
Turkmen, K. [1 ]
Tufan, F. [2 ]
Alpay, N. [3 ]
Kasikcioglu, E. [3 ]
Oflaz, H. [4 ]
Ecder, S. A. [6 ]
Ecder, T. [5 ]
机构
[1] Selcuk Univ, Meram Sch Med, Dept Nephrol, TR-42090 Konya, Turkey
[2] Istanbul Univ, Fac Med, Dept Geriatr, Istanbul, Turkey
[3] Istanbul Univ, Fac Med, Dept Internal Med, Istanbul, Turkey
[4] Istanbul Univ, Fac Med, Dept Cardiol, Istanbul, Turkey
[5] Istanbul Univ, Fac Med, Dept Nephrol, Istanbul, Turkey
[6] Goztepe Training Hosp, Dept Nephrol, Istanbul, Turkey
关键词
autosomal domimant polycystic disease; insulin resistance; coronary flow velocity reserve; LEFT-VENTRICULAR MASS; INTIMA-MEDIA THICKNESS; ENDOTHELIAL DYSFUNCTION; BLOOD-PRESSURE; YOUNG-ADULTS; HYPERTROPHY; ARTERY; HYPERINSULINEMIA; ECHOCARDIOGRAPHY; HYPERTENSION;
D O I
10.1111/j.1445-5994.2010.02404.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Cardiovascular problems are a major cause of morbidity and mortality in patients with autosomal dominant polycystic kidney disease (ADPKD). Aim: The aim of this study was to investigate coronary flow velocity reserve (CFVR) as a marker of endothelial dysfunction, carotid intima media thickness (CIMT) as a marker of subclinical organ damage and insulin resistance (IR) as a cardiovascular risk factor in patients with ADPKD. Methods: Twenty-two normotensive ADPKD patients with well-preserved renal function and 19 healthy subjects were included in the study. Creatinine clearances were calculated by the Cockcroft-Gault formula. The homeostasis model of IR (HOMA-IR) was used to measure IR. CIMT was measured by high-resolution vascular ultrasound. CFVR was calculated as the ratio of hyperaemic to baseline diastolic peak velocities by echocardiography. Results: There was no significant difference between the two groups regarding age, gender, body mass index, systolic and diastolic blood pressures, cholesterol and triglyceride levels. However, CIMT and HOMA-IR were significantly increased and CFVR was significantly decreased in patients with ADPKD compared with healthy subjects. Conclusions: The findings of decreased CFVR, increased CIMT and increased IR suggest that cardiovascular risk is elevated even in the early stages of ADPKD.
引用
收藏
页码:146 / 153
页数:8
相关论文
共 50 条
  • [1] Improvement of Coronary Flow Velocity Reserve with Telmisartan in Patients with Autosomal-Dominant Polycystic Kidney Disease
    Alisir, Sabahat
    Turkmen, Kultigin
    Alpay, Nilufer
    Elitok, Ali
    Oflaz, Huseyin
    Uslu, Bora
    Cimen, Arif
    Kasikcioglu, Erdem
    Tufan, Fatih
    Ecder, Tevfik
    SOUTHERN MEDICAL JOURNAL, 2010, 103 (05) : 409 - 413
  • [2] Insulin Resistance and Antropometric Measurements in Autosomal Dominant Polycystic Kidney Disease
    Kazancioglu, Rumeyza
    Memili, Vecihi
    Ozturk, Savas
    Gursu, Meltem
    Kutlu, Cigdem
    Buyukaydin, Banu
    Kucuk, Mehmet
    Sar, Fuat
    TURKISH NEPHROLOGY DIALYSIS AND TRANSPLANTATION JOURNAL, 2011, 20 (03): : 241 - 247
  • [3] Coronary aneurysms in patients with autosomal dominant polycystic kidney disease
    Hadimeri, H
    Lamm, C
    Nyberg, G
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1998, 9 (05): : 837 - 841
  • [4] Coronary flow velocity reserve and carotid intima media thickness in patients with autosomal dominant polycystic kidney disease: From impaired tubules to impaired carotid and coronary arteries
    Turkmen, Kultigin
    Oflaz, Huseyin
    Uslu, Bora
    Cimen, Arif O.
    Elitok, Ali
    Kasikcioglu, Erdem
    Alisir, Sabahat
    Tufan, Fatih
    Namli, Sule
    Uysal, Mukremin
    Ecder, Tevfik
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 3 (04): : 986 - 991
  • [5] INSULIN SENSITIVITY IN CHILDREN WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
    Dachy, Angelique
    De Rechter, Stephanie
    Breysem, Luc
    Vennekens, Rudi
    Mathieu, Chantal
    Casteels, Kristina
    Van Hoorenbeeck, Kim
    Jouret, Francois
    Mekahli, Djalila
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I755 - I756
  • [6] INSULIN SENSITIVITY IN CHILDREN WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
    Angelique, Dachy
    Stephanie, De Rechter
    Luc, Breysem
    Rudi, Vennekens
    Chantal, Mathieu
    Kristina, Casteels
    Kim, Van Hoorenbeeck
    Francois, Jouret
    Djalila, Mekahli
    PEDIATRIC NEPHROLOGY, 2022, 37 (11) : 2812 - 2812
  • [7] CAPD in patients with autosomal dominant polycystic kidney disease
    Hadimeri, H
    Johansson, AC
    Haraldsson, B
    Nyberg, G
    PERITONEAL DIALYSIS INTERNATIONAL, 1998, 18 (04): : 429 - 432
  • [8] Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
    Torres, Vicente E.
    Chapman, Arlene B.
    Devuyst, Olivier
    Gansevoort, Ron T.
    Grantham, Jared J.
    Higashihara, Eiji
    Perrone, Ronald D.
    Krasa, Holly B.
    Ouyang, John
    Czerwiec, Frank S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (25): : 2407 - 2418
  • [9] Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease
    Walz, Gerd
    Budde, Klemens
    Mannaa, Marwan
    Nuernberger, Jens
    Wanner, Christoph
    Sommerer, Claudia
    Kunzendorf, Ulrich
    Banas, Bernhard
    Hoerl, Walter H.
    Obermueller, Nicholas
    Arns, Wolfgang
    Pavenstaedt, Hermann
    Gaedeke, Jens
    Buechert, Martin
    May, Christoph
    Gschaidmeier, Harald
    Kramer, Stefan
    Eckardt, Kai-Uwe
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (09): : 830 - 840
  • [10] Autosomal dominant polycystic kidney disease
    Chow, Chern Li
    Ong, Albert C. M.
    CLINICAL MEDICINE, 2009, 9 (03) : 278 - 283